Analyst Research Report Snapshot

Title:

ZELTIA - TURNING A CORNER

Price:

$10.00

Provider:

Edison Investment Research

Date:

25 Feb 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ZEL.MC

Available for Immediate Download
Summary:

Zeltia is approaching a material catalyst this year in the form of the read-out from its Phase II study of lurbinectedin (PM01183) in platinum resistant ovarian cancer. If positive, this could form the basis of a licensing deal that could transform Zeltia’s fortunes. This, and the more positive sales outlook for Yondelis (trabectedin), which has been hampered by recent Doxil supply shortages, should support further pipeline development and ultimately help Zeltia transition into a cancer pure-play.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.